ATE472602T1 - Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie - Google Patents

Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie

Info

Publication number
ATE472602T1
ATE472602T1 AT06291205T AT06291205T ATE472602T1 AT E472602 T1 ATE472602 T1 AT E472602T1 AT 06291205 T AT06291205 T AT 06291205T AT 06291205 T AT06291205 T AT 06291205T AT E472602 T1 ATE472602 T1 AT E472602T1
Authority
AT
Austria
Prior art keywords
mycobacteria
under
promoter active
control
hypoxic conditions
Prior art date
Application number
AT06291205T
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE472602T1 publication Critical patent/ATE472602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT06291205T 2006-07-25 2006-07-25 Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie ATE472602T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie

Publications (1)

Publication Number Publication Date
ATE472602T1 true ATE472602T1 (de) 2010-07-15

Family

ID=37026080

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06291205T ATE472602T1 (de) 2006-07-25 2006-07-25 Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie
AT07825556T ATE502110T1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07825556T ATE502110T1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Country Status (10)

Country Link
US (2) US20090304637A1 (de)
EP (2) EP1882741B1 (de)
JP (1) JP2009544305A (de)
AT (2) ATE472602T1 (de)
CA (1) CA2658713A1 (de)
DE (2) DE602006015180D1 (de)
DK (1) DK1882741T3 (de)
ES (1) ES2347812T3 (de)
HK (1) HK1112753A1 (de)
WO (1) WO2008012693A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
EP2882461A4 (de) * 2012-08-10 2016-08-17 Sloan Kettering Inst Cancer Vorhersage der blasenkrebsreaktion auf bcg
US10494665B2 (en) * 2014-08-20 2019-12-03 Huawei Yang Test kit and method for testing target nucleic acid in sample
EP3555627B1 (de) 2016-12-14 2023-11-22 Purdue Research Foundation Auf fibroblastenaktivierungsprotein (fap) gerichtete bildgebung und therapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
US7022320B1 (en) * 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
EP1523331B1 (de) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutisches vakzin gegen tuberkulosis
DK2206514T3 (da) * 2003-10-16 2014-04-22 Univ California Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
EP1694829B1 (de) * 2003-12-02 2010-08-04 Institut Pasteur Neuer mit sars verbunden coronavirus stamm und seine verwendungen

Also Published As

Publication number Publication date
EP2049667B1 (de) 2011-03-16
EP1882741A1 (de) 2008-01-30
ATE502110T1 (de) 2011-04-15
JP2009544305A (ja) 2009-12-17
US20120156169A1 (en) 2012-06-21
DE602006015180D1 (de) 2010-08-12
DK1882741T3 (da) 2010-10-11
WO2008012693A3 (en) 2008-04-24
WO2008012693A2 (en) 2008-01-31
HK1112753A1 (en) 2008-09-12
EP2049667A2 (de) 2009-04-22
ES2347812T3 (es) 2010-11-04
DE602007013248D1 (de) 2011-04-28
EP1882741B1 (de) 2010-06-30
US20090304637A1 (en) 2009-12-10
CA2658713A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
AR088737A1 (es) Familia de toxinas inhibidoras de insectos activa contra insectos hemipteros y/o lepidopteros
UA99452C2 (ru) Способ стимулирования миелинизации и дифференцирования олигодендроцитов путем применения семафорина 6a
PH12014501336A1 (en) Glucagon analogues
ATE472602T1 (de) Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
WO2016100241A3 (en) Methods for controlled activation or elimination of therapeutic cells
WO2008104953A3 (en) Methods and targets for identifying compounds for regulating rhinovirus infection
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
AU2010327936A8 (en) Agents and methods for treating ischemic and other diseases
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
TN2012000560A1 (en) Glucagon analogues
UA106458C2 (uk) Чутливий до сульфонілсечовини репресорний білок
HK1126856A1 (en) Methods for identifying polypeptide targets
WO2011082382A3 (en) Methods for detecting and regulating alopecia areata and gene cohorts thereof
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
NZ702178A (en) Lingo-2 antagonists for treatment of conditions involving motor neurons
MX365899B (es) Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
BR112022009898A2 (pt) Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1
WO2008005487A3 (en) Peptide sequences for modulation of protein kinase c
EA201370196A1 (ru) Антитела, которые связывают фактор роста опухоли-альфа и эпирегулин
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
DOP2007000020A (es) Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1882741

Country of ref document: EP